{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:10:12Z","timestamp":1786975812303,"version":"build-2736575974"},"reference-count":12,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2021,3,1]]},"DOI":"10.1001\/jamaoncol.2020.6166","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T14:21:22Z","timestamp":1607005282000},"page":"436","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer"],"prefix":"10.1001","volume":"7","author":[{"given":"Anant","family":"Ramaswamy","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Ostwal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr B.R.A Institute-Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat","family":"Bhargava","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujay","family":"Srinivas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Goel","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shraddha","family":"Patkar","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarika","family":"Mandavkar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Jadhav","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Parulekar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitkumar","family":"Choudhari","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"cbr200020r1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.v68.6","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"14","key":"cbr200020r2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"cbr200020r3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejca.2019.10.004","article-title":"Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial.","volume":"123","author":"Sharma","year":"2019","journal-title":"Eur J Cancer"},{"issue":"12","key":"cbr200020r4","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","article-title":"Second-line chemotherapy in advanced biliary cancer: a systematic review.","volume":"25","author":"Lamarca","year":"2014","journal-title":"Ann Oncol"},{"key":"cbr200020r5","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/JCO.2019.37.15_suppl.4003","article-title":"ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin \/ 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced \/ metastatic biliary tract cancers (ABC) previously-treated with cisplatin\/gemcitabine (CisGem) chemotherapy.","volume":"37","author":"Lamarca","year":"2019","journal-title":"JCO"},{"issue":"6","key":"cbr200020r6","first-page":"2619","article-title":"A pilot study of salvage irinotecan monotherapy for advanced biliary tract cancer.","volume":"33","author":"Sasaki","year":"2013","journal-title":"Anticancer Res"},{"issue":"3","key":"cbr200020r7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41416-018-0138-2","article-title":"A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin.","volume":"119","author":"Zheng","year":"2018","journal-title":"Br J Cancer"},{"issue":"3","key":"cbr200020r8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s12029-016-9828-2","article-title":"Second-Line Palliative Chemotherapy in Advanced Gall Bladder Cancer, CAP-IRI: Safe and Effective Option.","volume":"47","author":"Ramaswamy","year":"2016","journal-title":"J Gastrointest Cancer"},{"issue":"1","key":"cbr200020r9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/jjco\/hyh006","article-title":"Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy.","volume":"34","author":"Chun","year":"2004","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"cbr200020r10","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S1470-2045(18)30140-2","article-title":"Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.","volume":"19","author":"Xu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"cbr200020r11","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/0959-8049(94)00216-R","article-title":"A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil.","volume":"30A","author":"Beck","year":"1994","journal-title":"Eur J Cancer"},{"issue":"10","key":"cbr200020r12","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/cas.2001.92.issue-10","article-title":"High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro.","volume":"92","author":"Habara","year":"2001","journal-title":"Jpn J Cancer Res"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2773377\/jamaoncology_ramaswamy_2020_br_200020_1615397450.58172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T11:01:57Z","timestamp":1616065317000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2773377"}},"subtitle":["A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT)"],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.6166","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}